Advertisement

Biochemical Genetics

, Volume 51, Issue 9–10, pp 780–788 | Cite as

Prevalence of MTHFR C677T Single Nucleotide Polymorphism in Genetically Isolated Populations in Jordan

  • Rana Dajani
  • Raja Fathallah
  • Ala Arafat
  • Mohammed Emad AbdulQader
  • Nancy Hakooz
  • Yousef Al-Motassem
  • Mohammad El-Khateeb
Article

Abstract

Methylenetetrahydrofolate reductase (MTHFR) C677T single nucleotide polymorphism is a major inherited risk factor of venous thromboembolism. We sought to determine its prevalence in genetically isolated populations of Chechens and Circassians in Jordan. The MTHFR C677T mutation was analyzed from blood samples taken from 120 random unrelated Chechens and 72 Circassians. The prevalence of the MTHFR mutation in the Chechen population was 27.5% (allele frequency 15%); the prevalence among the Circassians was 50% (allele frequency 29.2%). The prevalence in the Chechen population is similar to that in Jordan and other world populations, but it is higher in the Circassian population. This study will contribute to understanding the interaction between genetic and environmental risk factors underlying thrombosis and will be useful in deciding which genetic variants should be tested in a clinical genetic testing service.

Keywords

Venous thrombophilia Prevalence MTHFR Chechen Circassian 

Notes

Acknowledgments

This study has been supported by the Hashemite University, Zarqa, Jordan. We would like to thank the Circassian and Chechen communities for their participation in this study. We would also like to thank the National Center for Diabetes, Genetics and Endocrinology, Amman, Jordan for allowing us to use their facilities.

References

  1. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB (1999) Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 61(4):265–267PubMedCrossRefGoogle Scholar
  2. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE (1995) Serum total homocysteine and coronary heart disease. Int J Epidemiol 24(4):704–709PubMedCrossRefGoogle Scholar
  3. Barbujani G, Nasidze IS, Whitehead GN (1994) Genetic diversity in the Caucasus. Hum Biol 66(4):639–668PubMedGoogle Scholar
  4. Bauduer F, Lacombe D (2005) Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T and population genetics. Mol Genet Metab 86(1–2):91–99PubMedCrossRefGoogle Scholar
  5. Bu R, Gutierrez MI, Al-Rasheed M, Belgaumi A, Bhatia K (2004) Variable drug metabolism genes in Arab population. Pharmacogenomics J 4(4):260–266PubMedCrossRefGoogle Scholar
  6. Bulayeva KB (2006) Overview of genetic-epidemiological studies in ethnically and demographically diverse isolates of Dagestan, Northern Caucasus. Russia. Croat Med J 47(4):641–648Google Scholar
  7. Chou YC, Wu MH, Yu JC, Lee MS, Yang T, Shih HL, Wu TY, Sun CA (2006) Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan. Carcinogenesis 27(11):2295–2300PubMedCrossRefGoogle Scholar
  8. Dajani R, Fatahallah R, Dajani A, Al-Shboul M, Khader Y (2012) Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan. Mol Biol Rep 39(9):9133–9138PubMedCrossRefGoogle Scholar
  9. Dajani R, Arafat A, Hakooz N, Al-Abbadi Z, Yousef A, El Khateeb M, Quadan F (2013) Polymorphisms in factor II and factor V thrombophilia genes among Circassians in Jordan. J Thromb Thrombolysis 35(1):83–89PubMedCrossRefGoogle Scholar
  10. de Bree A, Verschuren WM, Bjorke-Monsen AL, van der Put NM, Hell SG, Trijbels FJ, Blom HJ (2003) Effect of the methylenetetrahydrofolate reductase 677C→T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 77(3):687–693PubMedGoogle Scholar
  11. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334(12):759–762CrossRefGoogle Scholar
  12. Dissanayake VH, Weerasekera LY, Gammulla CG, Jayasekara RW (2009) Prevalence of genetic thrombophilic polymorphisms in the Sri Lankan population: implications for association study design and clinical genetic testing services. Exp Mol Pathol 87(2):159–162PubMedCrossRefGoogle Scholar
  13. Eid SS, Rihani G (2004) Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians. Clin Lab Sci 17(4):200–202PubMedGoogle Scholar
  14. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ (1995) Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 56(1):142–150PubMedGoogle Scholar
  15. Falik-Zaccai TC, Haron Y, Eilat D, Harash B, Golinker E, Hussein O, Elsikovits R, Borochowitz Z, Linn S (2003) Coronary heart disease among Circassians in Israel is not associated with mutations in thrombophilia genes. Hum Biol 75(1):57–68PubMedCrossRefGoogle Scholar
  16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluitjmans LA, van den Heuvel LP (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113PubMedCrossRefGoogle Scholar
  17. Genest JJ Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR (1990) Plasma homocysteine levels in men with premature coronary artery disease. J Am Coll Cardiol 16(5):1114–1119PubMedCrossRefGoogle Scholar
  18. Gueant-Rodriguez RM, Gueant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, Namour F, Chabi NW, Sanni A, Anello G, Bosco P, Romano C, Amouzou E, Arrieta HR, Sanchez BE, Romano A, Herbeth B, Guilland JC, Mutchinick OM (2006) Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr 83(3):701–707PubMedGoogle Scholar
  19. Herrmann FH, Salazar-Sanchez L, Schuster G, Jimenez-Arce G, Grimm R, Gomez X, Chavez M, Wulff K, Schroder W (2004) Prevalence of eight molecular markers associated with thrombotic diseases in six Amerindian tribes and two African groups of Costa Rica. Am J Hum Biol 16(1):82–86PubMedCrossRefGoogle Scholar
  20. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR (1999) Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 81(5):733–738PubMedGoogle Scholar
  21. Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, Saag KG, McNicholl J, Moreland LW, Alarcon GS, Bridges SL Jr (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65(9):1213–1218PubMedCrossRefGoogle Scholar
  22. Kailani W (2002) Chechens in the Middle East: between original and host cultures. Caspian Studies Program event report. Harvard University, CambridgeGoogle Scholar
  23. Kang SS, Passen EL, Ruggie N, Wong PW, Sora H (1993) Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 88(4 Pt 1):1463–1469PubMedCrossRefGoogle Scholar
  24. Kelemen LE, Anand SS, Hegele RA, Stampfer MJ, Rosner B, Willett WC, Montague PA, Lonn E, Vuksan V, Teo KK, Devannesen S, Yusuf S (2004) Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis 176(2):361–370PubMedCrossRefGoogle Scholar
  25. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ (1996) Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58(1):35–41PubMedGoogle Scholar
  26. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U (1996) Inherited thrombophilia, Part 1. Thromb Haemost 76(5):651–662PubMedGoogle Scholar
  27. Nasidze I, Ling EY, Quinque D, Dupanloup I, Cordaux R, Rychkov S, Naumova O, Zhukova O, Sarraf-Zadengan N, Naderi GA, Asgary S, Sardas SM, Farhud DD, Sarkisian T, Asadov C, Kerimov A, Stoneking M (2004) Mitochondrial DNA and Y-chromosome variation in the Caucasus. Ann Hum Genet 68(3):205–221PubMedCrossRefGoogle Scholar
  28. Ray JG (1998) Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 158(19):2101–2106PubMedCrossRefGoogle Scholar
  29. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchane K, Savon SR, Selhub J, Nissen SE (1995) Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 92(10):2825–2830PubMedCrossRefGoogle Scholar
  30. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346(8982):1070–1071PubMedCrossRefGoogle Scholar
  31. Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Stenling R, Riboli E, Winkvist A, Palmqvist R (2006) Low folate levels may protect against colorectal cancer. Gut 55(10):1461–1466PubMedCrossRefGoogle Scholar
  32. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC (1996) Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 143(9):845–859PubMedCrossRefGoogle Scholar
  33. Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338(15):1042–1050PubMedCrossRefGoogle Scholar
  34. Whitehead AS, Gallagher P, Millis JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC, Scott JM (1995) A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. QJM 88(11):763–766PubMedGoogle Scholar
  35. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, Stoll C, Alembik Y, Dot B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, Lopez MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martinez-Frias ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD (2003) Geographical and ethnic variation of the 677C→T allele of 5,10-methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40(8):619–625PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Rana Dajani
    • 1
  • Raja Fathallah
    • 2
  • Ala Arafat
    • 2
  • Mohammed Emad AbdulQader
    • 3
  • Nancy Hakooz
    • 4
  • Yousef Al-Motassem
    • 4
  • Mohammad El-Khateeb
    • 2
  1. 1.Department of Biology and BiotechnologyHashemite UniversityZarqaJordan
  2. 2.National Center for DiabetesGenetics and EndocrinologyAmmanJordan
  3. 3.Faculty of MedicineHashemite UniversityZarqaJordan
  4. 4.Department of Biopharmaceutics and Clinical Pharmacy, College of PharmacyUniversity of JordanAmmanJordan

Personalised recommendations